Anteris Technologies (AVR) H2 2024 earnings summary

Executive summary

• Focused on developing and commercializing the DurAVR® THV system, a novel single-piece transcatheter heart valve for aortic stenosis, leveraging proprietary ADAPT® anti-calcification tissue technology and the ComASUR® delivery system.

• Completed an IPO in December 2024, raising $80.1 million in net proceeds, and reorganized as a Delaware corporation.

• As of December 31, 2024, had 136 full-time equivalent employees and operations in the US, Australia, and Switzerland.

Financial highlights

• Net sales for 2024 were $2.7 million, down 1% from 2023, primarily from tissue product sales.

• Net loss after tax was $76.0 million in 2024, a 62% increase from $46.8 million in 2023, driven by higher R&D and SG&A expenses.

• R&D expenses rose 67% to $51.5 million, mainly due to Pivotal Trial preparations and manufacturing scale-up.

• SG&A expenses increased 62% to $28.2 million, reflecting IPO-related costs, stock option grants, legal provisions, and headcount growth.

• Cash and cash equivalents at year-end were $70.5 million, up from $21.1 million in 2023, but management notes current cash is insufficient for the next 12 months without additional financing.

• Accumulated deficit reached $276.4 million as of December 31, 2024.

Outlook and guidance

• Anticipates continued operating losses and negative cash flows until regulatory approval and commercialization of DurAVR® THV.

• Plans to submit an IDE for the Pivotal Trial in Q1 2025, with enrollment expected to begin in Q3 2025.

• Expects to require substantial additional funding to achieve long-term goals and complete R&D.